ReviewEndocrine2015
GH and the cardiovascular system: an update on a topic at heart.
Review in Endocrine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02322034 (Effects of Interval Training on Hormonal Pathways in Chronic Heart Failure), which is not on this map. Cited by 66 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Interval Training on Hormonal Pathways in Chronic Heart Failure
Who cites it
66 citing papers in PubMed, 6 syntheses or guidelines pooled it, 141 citations in OpenAlex.
- GH Therapy in Chronic Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials.The Journal of clinical endocrinology and metabolism · 2025Pooled it
- Somatic growth in single ventricle patients: A systematic review and meta-analysis.Acta paediatrica (Oslo, Norway : 1992) · 2023Pooled it
- New insights on the cardiovascular effects of IGF-1.Frontiers in endocrinology · 2023Pooled it
- MRI Assessment of Cardiac Function and Morphology in Adult Patients With Growth Hormone Deficiency: A Systematic Review and Meta-Analysis.Frontiers in endocrinology · 2022Pooled it
- Cardiovascular effects of growth hormone (GH) treatment on GH-deficient adults: a meta-analysis update.Pituitary · 2020Pooled it
- GH Supplementation Effects on Cardiovascular Risk in GH Deficient Adult Patients: A Systematic Review and Meta-analysis.Endocrine, metabolic & immune disorders drug targets · 2017Pooled it
- Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial.The Journal of clinical endocrinology and metabolism · 2021Trial
- The Effect of 3-Month Growth Hormone Administration and 12-Month Follow-Up Duration among Heart Failure Patients Four Weeks after Myocardial Infarction: A Randomized Double-Blinded Clinical Trial.Cardiovascular therapeutics · 2021Trial
- Acromegaly and cardiovascular disease: mechanisms, clinical impact, and evolving management.Endocrine reviews · 2026Review
- Cardiac Resynchronization Therapy With Defibrillator for Acromegalic Cardiomyopathy With Left Bundle Branch Block.JACC. Case reports · 2026Article
- Prevalence and evolution of hypertension in a large Iberian cohort of patients with acromegaly.Pituitary · 2025Article
- Cardiac Endocrine Function and Hormonal Interplay in Pediatrics: From Development to Clinical Implications.Biomedicines · 2025Review
- Effects of Hormones on Left Heart Structure and Function with Echocardiography in Acromegaly.Reviews in cardiovascular medicine · 2025Article
- Long-Acting Growth Hormone for Pediatric Growth Hormone Deficiency.Journal of the Endocrine Society · 2025Review
- Copeptin and Mid-Regional Proadrenomedullin Are Not Useful Biomarkers of Cardiometabolic Disease in Patients with Acromegaly-A Preliminary Study.Biomedicines · 2025Article
- Growth hormone-releasing hormone and its analogues in health and disease.Nature reviews. Endocrinology · 2025Review
- Diastolic Dysfunction with Normal Ejection Fraction and Reduced Heart Rate in Mice Expressing Human Growth Hormone and Displaying Signs of Growth Hormone Insufficiency.International journal of molecular sciences · 2024Article
- Article
- The Double-Edged Sword of Total Antioxidant Capacity: Clinical Significance and Personal Experience.Antioxidants (Basel, Switzerland) · 2024Review
- Serum insulin-like growth factor-1 as a potential prognostic biomarker for heart failure with reduced ejection fraction: a meta-analysis.Frontiers in cardiovascular medicine · 2024Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this review, the importance of growth hormone (GH) for the maintenance of normal cardiac function in adult life is discussed. Physiological effects of GH and underlying mechanisms for interactions between GH and insulin-like growth factor I (IGF-I) and the cardiovascular system are covered as well as the cardiac dysfunction caused both by GH excess (acromegaly) and by GH deficiency in adult hypopituitary patients. In both acromegaly and adult GH deficiency, there is also increased cardiovascular morbidity and mortality possibly linked to aberrations in GH status. Finally, the status of the GH/IGF-I system in relation to heart failure and the potential of GH as a therapeutic tool in the treatment of heart failure are reviewed in this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.